Acute myeloid leukemia
Conditions
Interventions
Experimental group
:Subcutaneous injection of ropivastine N01 (5 µg/kg) was administered on the 3rd and 10th days post-transplantation, with a total of 2 doses.
Sponsors
The First Affiliated Hospital of Guilin Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1: Malignant hematologic disease patients aged 18-65 years who have undergone allogeneic hematopoietic stem cell transplantation (allo-HSCT) 2: Sign the informed consent form
Exclusion criteria
Exclusion criteria: 1: Active infection (CRP> 50 mg/L or PCT> 0.5 ng/mL) 2: Severe hepatic and renal dysfunction (ALT> 3 times the upper limit of normal, Cr> 2 times the upper limit of normal) 3: History of thrombosis or hereditary thrombotic predisposition
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| platelet implantation time; | — |
Secondary
| Measure | Time frame |
|---|---|
| platelet recovery rate within 100 days post-transplantation;proportion of Treg cells and CD4+ T cells;proportion of NKG2D on NK cell surface; | — |
Countries
China
Contacts
Public Contactxiaotao wang
The First Affiliated Hospital of Guilin Medical University
Outcome results
None listed